| 摘要 |
This study reports a case of a 63-year-old female patient who developed euglycemic diabetic ketoacidosis (euDKA) within 24 h adding Empagliflozin. Upon admission, the patient’s fasting blood glucose was 14.7 mmol/L and glycated hemoglobin (HbA1c) was 7.9%. She had been using insulin combined with repaglinide for long-term blood glucose control. On the next day after initiating Empagliflozin, persistent positive urine ketones were detected, with blood glucose fluctuating between 7.8-14.7 mmol/L. Serum bicarbonate was normal (32.0 mmol/L), and there were no typical symptoms of acidosis. After discontinuing Empagliflozin, receiving intravenous fluid rehydration, and low-dose insulin therapy, urine ketones gradually turned negative. This case suggests that in clinical practice, it is necessary to achieve a precise balance between cardiovascular benefits and metabolic risks, adhering to the principle of individualized medication. |
